Skip to content
Use case 142

Pharmacy Dispensing Workstations

A deployment concept for pharmacies, hospitals, dispensing vendors and medication safety teams.

Proposed deployment · Compatibility assessment required
Healthcare and Life Sciences

Why this environment matters

Security for pharmacy dispensing workstations starts with the system's role: it supports prescription review, stock selection, labelling and medicine supply. A key concern is that malware or account misuse can alter labels, expose prescriptions or assist diversion of controlled medicines. NØNOS offers a potential architecture based on signed capsules, explicit capabilities and strong isolation.

The security challenge

The threat model should assume that one component will eventually fail or be exploited. In this case, malware or account misuse can alter labels, expose prescriptions or assist diversion of controlled medicines. Healthcare systems process deeply sensitive data while supporting time-critical clinical decisions. Security must improve trust without delaying care or obscuring the human responsibility for treatment. The aim is to prevent that single failure from automatically gaining the keys, devices, records and network paths of the whole platform.

How the capsule model could help

A candidate NØNOS architecture would separate clinical review, label generation, inventory adjustment and privileged drug-management functions with signed software. The design would prioritise signed clinical software and isolated medical file parsers, supported by minimal sensitive persistence and attested privileged sessions. Each capsule would carry a declared policy for files, networks, devices and secrets, and unknown or altered software would not receive the same authority as an approved component.

Separate address spaces and capability checks can limit cross-process reach. They cannot stop harmful use of legitimate permissions, prove AI decisions correct or substitute for domain-specific safety controls.

Deployment requirements

Clinical deployment would require medical-device validation, patient-safety risk management, privacy review, human factors testing and integration with existing approved workflows. Security controls must never obstruct emergency care.

Current public-beta limitations, hardware support and application availability must be assessed before any pilot. Neither this use case nor an industry source establishes NONOS certification or a current customer deployment.

Who could buy or integrate it?

  • Pharmacy automation manufacturers integrating operator workstations
  • Hospital pharmacies purchasing dispensing system upgrades
  • Retail pharmacy chains procuring automated dispensing terminals

Industry examples: Omnicell, ScriptPro. Organisations shown illustrate the industry. No NONOS customer, partner or endorsement relationship is implied.

Market opportunity

Market benchmarks and device scenarios.

Published industry benchmark
US$7.3 billion

Pharmacy automation devices

Global · 2025 · annual market estimate

Medication dispensing, packaging, labeling, storage and compounding automation.

Modelled global devices
400K–4.8M

Candidate OS endpoints

Hypothetical planning range · 2025

Low confidence: planning assumptions. Hardware compatibility, procurement and adoption have not been validated.

Illustrative annual licensing
$16M–$864M

USD / year at full model coverage

Device scenario × assumed US$40–$180 per device / year.

Not a revenue forecast, announced price or measured serviceable market.

Device calculation

Hypothetical global planning range, 2025 scenario: assume 200,000–800,000 community and hospital dispensing pharmacies × 2–6 candidate OS endpoints per site/asset = 400,000–4,800,000 endpoints. Counting unit: dispensing, controlled-drug and verification workstations. Site and asset counts, and devices per site, are planning assumptions. The installed base has not been measured. Coverage is limited to the defined equipped subset; includes all candidate endpoints within that assumed subset. Hardware eligibility, certification, adoption and achievable NØNOS share are unverified; overlaps other cases.

Pharmacy Automation Devices Market Report, 2026-2033 ↗

Market context only; separate from device and site population estimates. Original monetary-market scope and geography are preserved in benchmark. This source does not establish the assumed worldwide site count or endpoint density.

How to interpret the figures

Adjacent or broader commercial market benchmark; not the NØNOS OS market, licensable-device count or revenue forecast.

Modelled candidate endpoints multiplied by an assumed annual USD price per endpoint. Pricing is a planning assumption, not a vendor quote. This illustrates the full scenario range, not revenue or total addressable market. It excludes adoption timing, procurement, certification, support costs, channel economics and achievable market share. Use cases can overlap, so their totals do not represent unique devices.

Research from 2026. Publisher estimates have not been independently audited.

Read the full methodology

Explore NONOS

Choose your
NONOS experience.

Discover the platform for your organisation or explore the software.

You can reopen this chooser from the footer at any time.